Herbalife Q4 net sales up 2.9% YoY to $1.2B; full-year net sales down 2.7% to $5.1B; initiates refinancing of 2018 loans

HERBALIFE LTD.

2023-FY EPS reported $1.42 revenue$5,062,400,000

Q4 net sales $1.2B, up 2.9% YoY (2.5% constant currency); net income $10.2M, diluted EPS $0.10.
Full-year 2023 net sales $5.1B, down 2.7% vs 2022; net income $142.2M, diluted EPS $1.42, adjusted EPS $2.21.
Adjusted EBITDA Q4 $108.8M, full-year $570.6M; free cash flow $222.5M, operating cash flow $357.5M.
Transformation Program cost savings of ~$70M realized in 2023; pre-tax expenses ~$12M in Q4.
Refinancing initiated for 2018 Term Loan A and Revolving Credit Facility (due March 2025); Annual Meeting April 25, 2024.

item 2.02 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

HERBALIFE LTD. reported fourth fiscal quarter and fiscal year ended December 31, 2023 results: revenue $1.2 billion, net income $10.2 million, EPS $0.10.

Period: fourth fiscal quarter and fiscal year ended December 31, 2023
Revenue: $1.2 billion
Net income: $10.2 million
EPS: $0.10
Result: reported results

Exact text from the filing

year-over-year net sales growth on both reported and constant currency basis 1 Fourth consecutive quarter of improved year-over-year reported net sales trends Net sales of $1.2 billion, up 2.9% vs. 4Q ‘22; on constant currency basis 1 , net sales increased 2.5% vs. 4Q ‘22 Net income of $10.2 million and adjusted EBITDA 2 of $108.8 million Diluted EPS of $0.10

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

HERBALIFE LTD. filing history →

Source: SEC EDGAR

accession 0001157523-24-000245

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.